MX2020009275A - Composiciones de anticuerpo anti-pd-1. - Google Patents
Composiciones de anticuerpo anti-pd-1.Info
- Publication number
- MX2020009275A MX2020009275A MX2020009275A MX2020009275A MX2020009275A MX 2020009275 A MX2020009275 A MX 2020009275A MX 2020009275 A MX2020009275 A MX 2020009275A MX 2020009275 A MX2020009275 A MX 2020009275A MX 2020009275 A MX2020009275 A MX 2020009275A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody compositions
- present
- antibody
- antibody formulation
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009275A true MX2020009275A (es) | 2021-01-08 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009275A MX2020009275A (es) | 2018-03-07 | 2019-03-04 | Composiciones de anticuerpo anti-pd-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (enExample) |
| EP (1) | EP3761954A1 (enExample) |
| JP (1) | JP7312188B2 (enExample) |
| KR (1) | KR102594028B1 (enExample) |
| CN (1) | CN112105343B (enExample) |
| AU (1) | AU2019232625B2 (enExample) |
| BR (1) | BR112020017935A2 (enExample) |
| IL (1) | IL277095B2 (enExample) |
| MX (1) | MX2020009275A (enExample) |
| WO (1) | WO2019171253A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| US20230035617A1 (en) * | 2019-11-13 | 2023-02-02 | Pfizer Inc. | Stable aqueous anti-tfpi antibody formulation |
| US20230054413A1 (en) * | 2019-12-13 | 2023-02-23 | Samsung Bioepis Co., Ltd. | Stable anti-pd1 antibody pharmaceutical formulations |
| SI4076385T1 (sl) | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| JP2023512286A (ja) * | 2020-01-31 | 2023-03-24 | サノフイ | 抗体の肺送達 |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| JP2024527517A (ja) * | 2021-06-23 | 2024-07-25 | フォーマイコン アーゲー | 抗ｐｄ１抗体製剤 |
| WO2023274275A1 (zh) * | 2021-07-01 | 2023-01-05 | 天津立博美华基因科技有限责任公司 | 药物组合及其用途 |
| CA3224640A1 (en) * | 2021-07-09 | 2023-01-12 | Krishnan SAMPATHKUMAR | Pharmaceutical compositions of a pd-1 antibody and use of the same |
| CN118076380A (zh) * | 2021-09-03 | 2024-05-24 | 雷迪博士实验室有限公司 | 免疫检查点抑制剂的药物配制物 |
| WO2023031969A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | A method of improving stability of immune check point inhibitors |
| IL314840A (en) * | 2022-03-07 | 2024-10-01 | Mabxience Res S L | Stable Antibody Formulations |
| EP4637818A1 (en) | 2022-12-21 | 2025-10-29 | Formycon AG | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| TW202508641A (zh) * | 2023-08-16 | 2025-03-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含免疫綴合物的醫藥組成物及其用途 |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| MX2007011767A (es) * | 2005-03-23 | 2007-10-18 | Pfizer Prod Inc | Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer. |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| PH12012502193A1 (en) * | 2010-05-06 | 2021-08-09 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| EA201391489A1 (ru) * | 2011-04-07 | 2014-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
| MY175472A (en) * | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| AR099812A1 (es) * | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| MX2017009759A (es) * | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| KR102770786B1 (ko) * | 2017-05-02 | 2025-02-20 | 머크 샤프 앤드 돔 엘엘씨 | 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법 |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019232625B2 (en) | 2025-12-11 |
| IL277095A (en) | 2020-10-29 |
| IL277095B1 (en) | 2025-06-01 |
| KR102594028B1 (ko) | 2023-10-24 |
| RU2020129226A (ru) | 2022-04-07 |
| CA3093036A1 (en) | 2019-09-12 |
| JP7312188B2 (ja) | 2023-07-20 |
| WO2019171253A8 (en) | 2020-10-01 |
| RU2020129226A3 (enExample) | 2022-04-07 |
| US20210002369A1 (en) | 2021-01-07 |
| KR20200128115A (ko) | 2020-11-11 |
| EP3761954A1 (en) | 2021-01-13 |
| CN112105343B (zh) | 2024-07-30 |
| CN112105343A (zh) | 2020-12-18 |
| WO2019171253A1 (en) | 2019-09-12 |
| JP2021517129A (ja) | 2021-07-15 |
| BR112020017935A2 (pt) | 2021-02-09 |
| IL277095B2 (en) | 2025-10-01 |
| AU2019232625A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009275A (es) | Composiciones de anticuerpo anti-pd-1. | |
| BR112017007393A2 (pt) | composições de anticorpo anti-il-7r | |
| CO2017007693A2 (es) | Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf) | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| WO2021021837A3 (en) | Anti-pvrig antibodies formulations and uses thereof | |
| MX372760B (es) | Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos. | |
| ECSP21060917A (es) | Formulación de anticuerpos terapéuticos | |
| EA201791733A1 (ru) | Производные 9h-пирролодипиридина | |
| CO2021003805A2 (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso | |
| CL2022000492A1 (es) | Proceso para la preparación de estetrol de alta pureza. | |
| JOP20210269A1 (ar) | تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| BR112021019959A2 (pt) | Anticorpo biespecífico, e, formulação farmacêutica | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
| CO2018007810A2 (es) | Formulación líquida estable de gonadotropina | |
| MX2021014961A (es) | Compuestos triciclicos y su uso. | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| MX2019005925A (es) | Composiciones de alergenos liquidas y metodos para la preparacion de las mismas. | |
| BR112022010143A2 (pt) | Inibidores de ahr e usos respectivos | |
| MX2022005836A (es) | Formulacion estable de anticuerpos acuosos. | |
| BR112014016804A8 (pt) | composições, métodos de uso e métodos de tratamento | |
| BR112018005931A2 (pt) | composições de anticorpo para hiv e métodos de uso |